DexCom, Inc.
DXCM NASDAQHealthcare ★★★★★Latest Earnings
Date
Jul 30, 2026
ET
EPS Est.
0.61
EPS Actual
0.70
Revenue Est.
$1.29B
Revenue Actual
$1.31B
Next Earnings Report
Date
Oct 29, 2026 · Thu
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
0.66
Revenue Est.
$1.33B
Company Overview
DexCom, Inc. (ticker DXCM) is listed on NASDAQ with a market cap of about $34.85B. Its next earnings report (FY2026 Q3) is expected on Oct 29, 2026 (ET), After-market, with consensus EPS of 0.66. In the last 15 reported quarters, EPS beat consensus estimates 13 times.
Actual EPS TrendRecently15Term · Feb 9, 2023 → Jul 30, 2026
Feb 9, 2023Range: 0.17 ~ 0.70Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | 0.61 | 0.70 | $1.29B | $1.31B |
| Apr 30, 2026 | -- | 0.47 | Above forecast↑0.56 | $1.17B | $1.19B |
| Feb 12, 2026 | -- | 0.65 | 0.68 | $1.25B | $1.26B |
| Oct 30, 2025 | -- | 0.58 | 0.61 | $1.18B | $1.21B |
| Jul 30, 2025 | -- | 0.44 | 0.48 | $1.12B | $1.16B |
| May 1, 2025 | -- | 0.33 | 0.32 | $1.02B | $1.04B |
| Feb 13, 2025 | -- | 0.48 | 0.45 | $1.11B | $1.11B |
| Oct 24, 2024 | -- | 0.44 | 0.45 | $990.4M | $994.2M |
| Jul 25, 2024 | -- | 0.39 | 0.43 | $1.04B | $1B |
| Apr 25, 2024 | -- | 0.27 | Above forecast↑0.32 | $909.9M | $921M |
| Feb 8, 2024 | -- | 0.43 | Above forecast↑0.50 | $1.01B | $1.03B |
| Oct 26, 2023 | -- | 0.34 | Above forecast↑0.50 | $939.2M | $975M |
| Jul 27, 2023 | -- | 0.23 | Above forecast↑0.34 | $841.6M | $871.3M |
| Apr 27, 2023 | -- | 0.15 | 0.17 | $720.7M | $741.5M |
| Feb 9, 2023 | -- | 0.26 | Above forecast↑0.34 | $810.1M | $815.2M |
Original Filings (SEC)
10-Q2026-07-30 ↗
8-K2026-07-30 ↗
8-K2026-05-28 ↗
8-K2026-05-15 ↗
10-Q2026-04-30 ↗
8-K2026-04-30 ↗
8-K2026-03-02 ↗
8-K2026-02-26 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
